Product Description
Autologous CD19/CD20-directed CAR-T cells, single infusion intravenously. (Sourced from: https://clinicaltrials.gov/study/NCT06517004?term=JWCAR-201&rank=1)
Mechanisms of Action: CAR-T,CD19,CD20
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Fudan University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|